SOURCE: Paragon Financial Limited

Paragon Financial Limited

September 19, 2011 08:16 ET

Heightened FDA Scrutiny Threatens Zalicus and AEterna Zentaris

The Paragon Report Provides Equity Research on Zalicus & AEterna Zentaris

NEW YORK, NY--(Marketwire - Sep 19, 2011) - The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Zalicus, Inc. (NASDAQ: ZLCS) and AEterna Zentaris, Inc. (NASDAQ: AEZS) (TSX: AEZ). Access to the full company reports can be found at:

www.paragonreport.com/ZLCS

www.paragonreport.com/AEZS

In recent years the FDA has been heavily scrutinized for making the approval process more difficult for drug developers. A groundbreaking study released this year by the BIO and BioMedTracker finds that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is a mere ten percent. Previously the rate of approval was one in five to one in six. Oncology drugs faced the toughest road to approval despite the fact that the disease area is the most closely studied in all of drug development.

Janet Woodcock, the head of the FDA's drug division, is quick to dismiss concerns regarding the FDA's approval process. This summer in testimony before the House Energy and Commerce's health subcommittee, Woodcock explained the agency meets more than 90% of deadlines that are part of the drug-review process. She also said so-called first cycle approvals are at a 20-year high with and said more than two-thirds of new drugs being approved within the six-to-10-month time frames given to new drug applications.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The company recently posted a $4.4 million increase in research and development expenses, which were due primarily to an increase in expenses related to the clinical development of Synavive and preclinical program expenses related to our Ion channel product candidates.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. Recently the company reported positive late-stage results for its product used to diagnose adult growth hormone deficiency.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer.